The interval between methotrexate and leucovorin determines the efficacy of 5-fluorouracil modulation in vitro and in vivo.
van der Wilt
C L
CL
Dept. Medical Oncology, Free University Hospital, Amsterdam, The Netherlands.
de Jong
M
M
Braakhuis
B J
BJ
Pinedo
H M
HM
Peters
G J
GJ
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use* / Q000633:toxicity; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity*; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000494:pharmacology / Q000633:toxicity*; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity*; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D013997:Time Factors; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured
D002955:Leucovorin; D005472:Fluorouracil; D008727:Methotrexate